UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014777
Receipt number R000014489
Scientific Title Study on safety and efficacy of granulocyte transfusion mobilized with G-CSF in related donor
Date of disclosure of the study information 2014/08/13
Last modified on 2014/08/06 14:19:03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on safety and efficacy of granulocyte transfusion mobilized with G-CSF in related donor

Acronym

Granulocyte transfusion from related donor

Scientific Title

Study on safety and efficacy of granulocyte transfusion mobilized with G-CSF in related donor

Scientific Title:Acronym

Granulocyte transfusion from related donor

Region

Japan


Condition

Condition

Severe neutropenic patients following alloHSCT or chemotherapy

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Evaluate safety in both donor and recipient

Basic objectives2

Bio-equivalence

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase I


Assessment

Primary outcomes

Evaluate safety and efficacy in both donor and recipient

Key secondary outcomes

Overall survival in recipient at 30 days after granulocyte transfusion


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

Granulocyte transfusion

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

54 years-old >=

Gender

Male and Female

Key inclusion criteria

Recipient: Severe neutropenia, recovery is not expected within five days, severe infection with elevated CRP level or active focus to be fatal infection, written informed consent.
Donor: Relative within fourth degree, 20 to 54 years, compatible ABO blood type or minor incompatible, healthy donor, written informed consent.

Key exclusion criteria

Recipient: not expected to survive more than 30 days, self hematopoiesis is not expected to recover within 30 days.
Donor: allergy aginst G-CSF, pregnant or possible to be pregnant, breast feeding, history of thrombosisi or have risk of thrombosis, splenomegaly, comorbidiy or history of interstitial pneumonia, history of cancer, comorbidities of cardiac, pulmonary, renal diseases to be treated, comorbidities of inflammatory, autoimmune diseases to be treated.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazuyoshi Ishii

Organization

Kansai Medical University

Division name

First Department of Internal Medicine

Zip code


Address

2-5-1 Sinamachi, Hirakata, Osaka

TEL

072-804-2503

Email

ishiikaz@hirakata.kmu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Shinya Fujita

Organization

Kansai Medical University

Division name

First Department of Internal Medicine

Zip code


Address

2-5-1 Sinamachi, Hirakata, Osaka

TEL

072-804-2503

Homepage URL


Email

fujitas@hirakata.kmu.ac.jp


Sponsor or person

Institute

Kansai Medical University

Institute

Department

Personal name



Funding Source

Organization

Kansai Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

None

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

関西医科大学附属枚方病院(大阪府)
Kansai Medical University Hirakata Hospital (Osaka)


Other administrative information

Date of disclosure of the study information

2014 Year 08 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2013 Year 11 Month 23 Day

Date of IRB


Anticipated trial start date

2014 Year 01 Month 06 Day

Last follow-up date

2016 Year 01 Month 05 Day

Date of closure to data entry

2016 Year 04 Month 05 Day

Date trial data considered complete

2016 Year 05 Month 05 Day

Date analysis concluded

2016 Year 11 Month 05 Day


Other

Other related information



Management information

Registered date

2014 Year 08 Month 06 Day

Last modified on

2014 Year 08 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014489


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name